These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39253078)

  • 21. Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11.
    Sakashita K; Yoshida N; Muramatsu H; Ohtsuka Y; Watanabe K; Yabe M; Kakuda H; Honda Y; Watanabe T; Haba M; Ohmori S; Matsuda K; Yuza Y; Saito A; Horibe K; Adachi S; Manabe A
    Transplant Cell Ther; 2024 Jan; 30(1):105.e1-105.e10. PubMed ID: 37806448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
    Senapati J; Shoukier M; Garcia-Manero G; Wang X; Patel K; Kadia T; Ravandi F; Pemmaraju N; Ohanian M; Daver N; DiNardo C; Alvarado Y; Aldrich J; Borthakur G
    Am J Hematol; 2022 May; 97(5):574-582. PubMed ID: 35150150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches.
    Fabri O; Horakova J; Bodova I; Svec P; Laluhova Striezencova Z; Bubanska E; Cermak M; Galisova V; Skalicka K; Vaska A; Doczyova D; Panikova A; Sykora T; Adamcakova J; Kolenova A
    Neoplasma; 2019 Sep; 66(5):818-824. PubMed ID: 31129971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
    Mao S; Lin Y; Qin X; Miao Y; Luo C; Luo C; Wang J; Huang X; Zhu H; Lai J; Chen J
    Br J Haematol; 2024 Jun; 204(6):2332-2341. PubMed ID: 38622924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
    Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Li WY; Wang Y; Chen SN; Qiu HY; Fu ZZ; Wu DP; Sun AN
    Leuk Lymphoma; 2018 Jul; 59(7):1652-1658. PubMed ID: 29043875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical Study on Treatment of Juvenile Myelomonocytic Leukemia with Haploidentical-Hematopoietic Stem Cell Transplantation].
    Ding L; Zhu H; Han DM; Wang ZD; Zheng XL; Dong L; Yan HM; Liu J; Zhu L; Xue M; Guo ZK; Wang HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1524-1527. PubMed ID: 29070137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients.
    Pan M; Wu Y; Yang L; Zhu P; Shi J; Lai X; Liu L; Zhao Y; Yu J; Huang H; Luo Y
    Ann Hematol; 2024 Aug; 103(8):3105-3119. PubMed ID: 38829409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning.
    Li G; Sun Z; Geng L; Wan X; Zhu X; Tang B; Tong J; Yao W; Song K; Qiang P; Zhang L; Zhang X; Zhang S; Liu H
    Pediatr Transplant; 2022 Mar; 26(2):e14181. PubMed ID: 34747111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui JK; Xiao Y; You Y; Shi W; Li Q; Luo Y; Jiang L; Zhong ZD
    J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):693-698. PubMed ID: 29058281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
    Tang W; Fan X; Wang L; Hu J
    Medicine (Baltimore); 2015 Apr; 94(15):e706. PubMed ID: 25881847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful hematopoietic stem cell transplantation from an HLA-mismatched parent for engraftment failure after unrelated cord blood transplantation in patients with juvenile myelomonocytic leukemia: Report of two cases.
    Akahane K; Watanabe A; Furuichi Y; Somazu S; Oshiro H; Goi K; Sakashita K; Muramatsu H; Hama A; Takahashi Y; Koike K; Kojima S; Sugita K; Inukai T
    Pediatr Transplant; 2019 May; 23(3):e13378. PubMed ID: 30786117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
    Li Y; Cheng L; Xu C; Chen J; Hu J; Liu N; Lan S; Xie J; Sun T; Wang L; Zhang Y; Sun Y; Chen S; Hu L
    Front Oncol; 2021; 11():702239. PubMed ID: 34504785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
    Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
    BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia.
    Wang YX; Wang A; Su YF; Wang J; Li YH; Li F; Jing Y; Xu L; Wang YZ; Zheng X; Gao CJ; Hu LD; Gao XN; Liu DH
    Front Immunol; 2024; 15():1409302. PubMed ID: 39221255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
    Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183
    [No Abstract]   [Full Text] [Related]  

  • 40. Diagnosis and treatment of juvenile myelomonocytic leukemia.
    Liao XY; Qiu KY; Fang JP; Wu RH; Guo SY; Huang K; Zhou DH
    Hematology; 2019 Dec; 24(1):577-582. PubMed ID: 31389303
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.